Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients

Biomarkers

Volumn 19, Issue 6, 2014, Pages 452-456

  Ciancarelli, Irene ^a,b   De Amicis, Daniela ^a   Di Massimo, Caterina ^a   Di Scanno, Carla ^a   Pistarini, Caterina ^c   D'Orazio, Nicolantonio ^d   Tozzi Ciancarelli, Maria Giuliana ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Nova Salus Nursing and Rehabilitation Center   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biomarkers; Huntington's disease; Neuronal oxidative damage; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; NEURON SPECIFIC ENOLASE; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; ENOLASE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUNTINGTON CHOREA; INDEPENDENCE; MALE; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PHYSICAL DISABILITY; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEOXYGUANOSINE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHOPYRUVATE HYDRATASE; SUPEROXIDE DISMUTASE;

EID: 84906350636     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.935955     Document Type: Article

References (33)

1. Al-Aubaidy HA, Jelinek HF. (2010). 8-Hydroxy-2-deoxy-guanosine identifies oxidative DNA damage in a rural prediabetes cohort. Redox Rep 15:155-60.
2. Andrew SE, Goldberg YP, Kremer B, et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntingtons disease. Nat Genet 4:398-403.
3. Armstrong MJ, Miyasaki JM. (2012). Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:59-603.
4. Aziz NA, Jurgens CK, Landwehrmeyer GB, et al.; EHDN Registry Study Group. (2009). Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology 73:1280-5.
5. Borowsky B, Warner J, Leavitt BR, et al. (2013). 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 21: 1934-41.
6. Butterfield DA, Howard BJ, La Fontaine MA. (2001). Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimers disease and Huntingtons disease. Curr Med Chem 8:815-28.
7. Butterfield DA, Bader Lange ML. (2009). Multifuctional roles of enolase in Alzheimers disease: beyond altered glucose metabolism. J Neurochem 111:915-33.
8. Chen CM, Wu YR, Cheng ML, et al. (2007). Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntingtons disease patients. Biochem Biophys Res Commun 359: 335-40.
9. Ciancarelli I, Di Massimo C, De Amicis D, et al. (2012). Evidence of redox unbalance in post-acute ischemic stroke patients. Curr Neurovasc Res 9:85-90.
10. Di Massimo C, Scarpelli P, Di Lorenzo N, et al. (2006). Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 78:1163-7.
11. Eidelberg D, Surmeier DJ. (2010). Brain networks in Huntingtons disease. J Clin Invest 121:484-92.
12. Hersch SM, Gevorkian S, Marder K, et al. (2006). Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH20dG. Neurology 66:250-2.
13. Hersch SM, Rosas HD. (2010). Biomarkers to enable the development of neuroprotective therapies for Huntingtons disease. In: Lo DC, Hughes RE, eds. Neurobiology of Huntingtons disease: applications to drug discovery. Boca Raton (FL): Chemical Rubber Company Press, Chapter 11, 267-83.
14. Klepac N, Relja M, Klepac R, et al. (2007). Oxidative stress parameters in plasma of Huntingtons disease patients, asymptomatic Huntingtons disease gene carriers and healthy subjects: a crosssectional study. J Neurol 254:1676-83.
15. Long JD, Matson WR, Juhl AE, et al.; the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. (2012). 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 46:625-34.
16. Mahoney FI, Barthel DW. (1965). Functional evaluation: the Barthel Index. Md State Med J 14:61-5.
17. Marangos PJ, Paul SM. (1981). Brain levels of neuron-specific and nonneuronal enolase in Huntingtons disease. Neurochem 37: 1338-40.
18. Montoya A, Bruce Price BH, Menear M, Lepage M. (2006). Brain imaging and cognitive dysfunctions in Huntingtons disease. J Psychiatry Neurosci 31:21-9.
19. Paulsen JS, Langbehn DR, Stout JC, et al.; Predict-HD Investigators and Coordinators of the Huntington Study Group. (2008). Detection of Huntingtons disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874-80.
20. Paulsen JS, Long JD, Johnson HJ, et al. (2014). Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78. doi: 10.3389/fnagi.2014.00078.
21. Perluigi M, Fai Poon H, Maragos W, et al. (2005). Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 4: 1849-61.
22. Polidori MC, Mecocci P, Browne SE, et al. (1999). Oxidative damage to mitochondrial DNA in Huntingtons disease parietal cortex. Neurosci Lett 272:53-6.
23. Reuben DB, Siu AL. (1990). An objective measure of physical function in elderly outpatients. J Am Geriatr Soc 38:1105-12.
24. Sassone J, Colciago C, Cislaghi G, et al. (2009). Huntingtons disease: the current state of research with peripheral tissues. Exp Neurol 219: 385-97.
25. Sayre LM, Perry G, Smith MA. (2008). Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172-88.
26. Shinozaki K, Oda S, Sadahiro T, et al. (2009). S-100B and neuronspecific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care [Online]. Available from: http://ccforum.com/ content/13/4/R121 [last accessed 22 July 2009].
27. Shoulson I. (1981). Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31: 1333-5.
28. Sorolla MA, Reverter-Branchat G, Tamarit J. (2008). Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667-78.
29. Stack EC, Matson WR, Ferrante RJ. (2008). Evidence of oxidant damage in Huntingtons disease: translational strategies using antioxidants. Ann N Y Acad Sci 1147:79-92.
30. Tabrizi SJ, Langbehn DR, Leavitt BR, et al; TRACK-HD investigators. (2009). Biological and clinical manifestations of Huntingtons disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791-801.
31. Tinetti ME. (1986). Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34:119-26.
32. Túnez I, Sánchez-López F, Agüera E, et al. (2011). Important role of oxidative stress biomarkers in Huntingtons disease. J Med Chem 54: 5602-6.
33. Zuccato C, Valenza M, Cattaneo E. (2010). Molecular mechanisms and potential therapeutical targets in Huntingtons disease. Physiol Rev 90: 905-81.